We are thrilled to announce Revilico Inc.’s official partnership with M9, marking a groundbreaking moment in artificial intelligence-driven drug discovery. This collaboration will empower researchers and medicinal chemists worldwide to accelerate drug development at a fraction of traditional costs—all while maintaining top-notch data privacy and operational flexibility.

Drug discovery has traditionally been a time-intensive and expensive undertaking, often requiring years of R&D before any tangible results come to light. The pharmaceutical industry, however, is experiencing a paradigm shift fueled by advances in AI, machine learning, and computational modeling. While many larger players in the space are currently in the development of their own AI systems, this leaves a large part of the ecosystem driving innovation; small cap pharma, mid cap pharma, and academic institutions left with inefficient traditional processes. High R&D burdens in the early phases and a lack of expertise in the AI space leaves many of these companies with no AI technology, creating greater disparity between small and large players across the industry. Revilico has built an end to end platform driving innovation from the earliest of stages, to augment processes with an engine that accelerates traditional wet lab discovery. Now with the commoditization of powerful reasoning models capturing the market’s attention, many have turned their focus to faster and smarter AI solutions, especially those that can radically transform how we identify and develop novel therapeutics.

At Revilico, we specialize in using AI and physics-driven technology to streamline the drug discovery process. Our core strengths include target identification, where we leverage scRNA-seq data, LLMs, and Knowledge Graphs to rapidly pinpoint potential drug targets. Our platform automates routine tasks, ensuring that large datasets can be processed efficiently for quick hypothesis testing and target validation. In high-throughput screening (HTS), we use Deep learning models to assess molecules across a comprehensive list of properties such as chemical traits, solubility, toxicity profiles, permeability, and hepatocyte toxicity. Our generative chemistry tools for lead optimization refine compounds in real time, identifying the pharmacophore, expanding lead sets, iterating on R-groups, and optimizing for specific properties of interest - driving enhancements of potency and safety while reducing both time and cost by up to 80% as proven through a variety of case studies.

Revilico’s approach to automation, innovation, and optimization is backed by extensive computational case studies, demonstrating consistent success in retrospective validations of FDA-approved molecules. Our studies involved screening hundreds of thousands of drug-like compounds assimilated with select FDA approved drugs, systematically identifying potent, clinically validated candidates within the top 10%, and in some cases, even the top 2% of our proposed lead compounds, based on activity, ADME profiles, and safety.

We have rigorously tested the accuracy of our protein-ligand interaction analyses, evaluated our protein toxicity panel, tested rigorously for solubility across many models, and verified our ability to identify druggable protein pockets, even in targets traditionally considered undruggable. Together, this robust framework underscores Revilico’s ability to deliver high-impact, clinically relevant insights.

As the need for even faster model performance increases, entering this new frontier requires efficiency at scale. That’s where M9’s advanced inference-at-source optimization layer shines, bringing data safety and inference speed to the forefront of our platform.

M9’s technology allows Revilico’s AI models to run on hardware as compact as a MacBook M3, drastically lowering operational overhead. What once demanded extensive servers and data centers can now be achieved on off-the-shelf devices. This efficiency is coupled with unparalleled flexibility: pharmaceutical labs can choose between cloud-based or on-premise deployment, ensuring data safety while providing the convenience of high-performance AI wherever it’s needed. From small biotech startups to global pharma giants, our partnership aims to deliver high-powered analytics to every corner of the industry—making “democratized AI” a tangible reality.

Our collaborative efforts are not just about pushing the boundaries of computational performance; they’re also about democratizing these tools for scientists worldwide. By shrinking hardware requirements and optimizing software models, we’re enabling secure, cost-effective solutions that maintain data privacy, ease compliance concerns, and safeguard intellectual property. With faster model training and inference, research teams can accelerate decision-making and focus on scientific innovation rather than logistical barriers.

This partnership exemplifies the new direction of drug discovery: harnessing AI and computational power at unprecedented speed and at scale. As industry trends continue to favor more robust and affordable solutions, our collaboration is positioned to meet those demands head-on—creating a ripple effect of innovation across biotech, academia, and healthcare.

In the coming months, we’ll be rolling out collaborative webinars, white papers, and case studies to demonstrate tangible outcomes from our integrated solutions. We’re committed to making these powerful tools accessible to a broad range of organizations, offering specialized packages for small labs and large enterprises alike.

Whether you’re a medicinal chemist, a biotech startup, or part of a global pharma enterprise, we invite you to explore the potential of Revilico's Drug Discovery Engine, driven by M9’s inference optimization platform. Together, we’re redefining how the world discovers and develops new therapeutics—faster, cheaper, and more intelligently than ever before.

Curious to see what’s next in AI-powered drug discovery? Contact us for an in-depth demo or explore our website to stay updated on the latest advancements. We’re just getting started, and there’s much more innovation ahead.

🔗 Revilico: https://revilico.bio/ 🔗 M9:https://momentumai.dev/

Let’s push the boundaries of discovery together.